NCT01507285 - Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 1999

Primary Completion Date

November 30, 1999

Study Completion Date

November 30, 1999

Conditions

DiabetesDiabetes Mellitus, Type 2Healthy

Interventions

DRUG

liraglutide

Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only

DRUG

placebo

Initial single dose followed by subsequent multiple s.c. (under the skin) doses

Trial Locations (1)

M15 6SH

Novo Nordisk Investigational Site, Manchester